Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy - 2Bowen Yang is reportedly leaving 'Saturday Night Live' after this week's episode
- 3Spots To Go Birdwatching All over the Planet
- 4The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- 5Go on A Careful spending plan: Modest Objections for Your List of must-dos
- I’m a doctor. Here are 10 science-backed tips to help you get healthier.
- Best Streaming Gadget for Your Home Theater
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- Well known SUVs With Low Energy Utilization In 2024
- Exploring the Market: Unsold Rams May Be Less expensive Than You Naturally suspect
- The Way to Business: Startup Illustrations Learned
- 25 of the world’s best sandwiches
- Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- Don’t let food poisoning crash your Thanksgiving dinner
